Plain-English translation of NCT05438459 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called GAIA-102, which uses specially prepared cells delivered directly into your abdomen to fight advanced stomach or pancreatic cancer that has caused fluid buildup. Researchers want to see if this treatment works better when given alone or when combined with pembrolizumab, an immunotherapy drug that helps your immune system fight cancer. The study has two parts: the first focuses on safety and finding the right dose, and the second tests how well the medication works at that dose.
Advanced stomach and pancreatic cancers that have spread to the abdomen are very difficult to treat, especially when standard chemotherapy stops working or causes too many side effects. This trial exists because doctors need new options for patients like you who have tried multiple prior treatments without success.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive GAIA-102 injected directly into your abdomen through a port, either as a single treatment or combined with an intravenous immunotherapy drug, over a 3-week period. You may also receive or continue standard chemotherapy depending on which study group you're assigned to. You'll need to come for regular clinic visits to have blood tests, imaging scans, and physical exams to check how you're tolerating the treatment and whether your cancer is responding.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Japan